Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

European Respiratory Journal

Volumn 38, Issue 4, 2011, Pages 888-894

  Pranger, A D ^a   Van Altena, R ^a   Aarnoutse, R E ^b   Van Soolingen, D ^b,c   Uges, D R A ^a   Kosterink, J G W ^a   Van Der Werfe, T S ^a   Alffenaar, J W C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Moxifloxacin; Pharmacokinetics; Rifampicin; Safety; Tuberculosis

Indexed keywords

MOXIFLOXACIN; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL RECORD; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; QT PROLONGATION; RETROSPECTIVE STUDY; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC HEPATITIS; TUBERCULOSIS; VOMITING;

ADULT; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; QUINOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 80051784562     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00176610     Document Type: Article

References (29)

1. van den Boogaard J, Kibiki GS, Kisanga ER, et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53: 849-862.
2. Poissy J, Aubry A, Fernandez C, et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54: 4765-4771.
3. College ter Beoordeling van Geneesmiddelen. The Medicines Evaluation Board. www.cbg-meb.nl Date last accessed: January 10, 2009. Date last updated: November 30, 2008.
4. Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-683.
5. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51: 576-582. (Pubitemid 46185275)
6. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-857. (Pubitemid 351358362)
7. Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651. (Pubitemid 39411014)
8. Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45: 1001-1007. (Pubitemid 47580349)
9. Weiner M, Burman W, Luo CC. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007; 51: 2861-2866. (Pubitemid 47206223)
10. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940-950. (Pubitemid 39141801)
11. Demolis JL, Kubitza D, Tenneze L, et al. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68: 658-666. (Pubitemid 32059992)
12. Valerio G, Bracciale P, Manisco V, et al. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003; 15: 66-70. (Pubitemid 36355891)
13. Codecasa LR, Ferrara G, Ferrarese M, et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med 2006; 100: 1566-1572. (Pubitemid 44109116)
14. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
15. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138. (Pubitemid 351212403)
16. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338. (Pubitemid 44156613)
17. Sacco F, Spezzaferro M, Amitrano M, et al. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Dig Liver Dis 2010; 42: 110-114.
18. Alffenaar JW, van Altena R, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009; 49: 1080-1082.
19. Stass H, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001; 40: Suppl. 1, 1-9. (Pubitemid 32295676)
20. Pranger AD, Alffenaar JW, Wessels AM, et al. Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography-tandem mass spectrometry method. J Anal Toxicol 2010; 34: 135-141.
21. van Klingeren B, Dessens-Kroon M, van der Laan T, et al. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol 2007; 45: 2662-2668. (Pubitemid 47295501)
22. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004; 23: 243-255. (Pubitemid 38669936)
23. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58: Suppl. 2, 29-36. (Pubitemid 29500082)
24. Proost JH, Eleveld DJ. Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets. Pharm Res 2006; 23: 2748-2759. (Pubitemid 44885363)
25. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. NIH publication no. 09-5410. Bethesda, NIH, 2010. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06- 14-Quick Reference-8.5x11.pdf.
26. Zareba W, Cygankiewicz I. Long QT syndrome and short QT syndrome. Prog Cardiovasc Dis 2008; 51: 264-278.
27. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 2008; 65: 1029-1038. (Pubitemid 351768736)
28. Viskin S, Justo D, Halkin A, et al. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003; 45: 415-427. (Pubitemid 36403114)
29. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245. (Pubitemid 12149145)